LAVA THERAPEUTICS NV (LVTX)
NL0015000AG6 - Common Stock
Taking everything into account, LVTX scores 3 out of 10 in our fundamental rating. LVTX was compared to 588 industry peers in the Biotechnology industry. The financial health of LVTX is average, but there are quite some concerns on its profitability. LVTX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
LVTX had negative earnings in the past year.
In the past year LVTX has reported a negative cash flow from operations.
In the past 5 years LVTX always reported negative net income.
LVTX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
LVTX has a Return On Assets (-41.27%) which is comparable to the rest of the industry.
LVTX has a Return On Equity of -82.02%. This is comparable to the rest of the industry: LVTX outperforms 51.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.27% | ||
| ROE | -82.02% | ||
| ROIC | N/A |
ROA(3y)-32.03%
ROA(5y)-56.37%
ROE(3y)-52.47%
ROE(5y)-105.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LVTX has a better Gross Margin (48.51%) than 79.86% of its industry peers.
The Profit Margin and Operating Margin are not available for LVTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.51% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
LVTX has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, LVTX has a worse debt to assets ratio.
2.2 Solvency
LVTX has an Altman-Z score of -1.32. This is a bad value and indicates that LVTX is not financially healthy and even has some risk of bankruptcy.
LVTX has a Altman-Z score of -1.32. This is comparable to the rest of the industry: LVTX outperforms 53.58% of its industry peers.
LVTX has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of LVTX (0.11) is worse than 64.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.32 |
ROIC/WACCN/A
WACC7.05%
2.3 Liquidity
A Current Ratio of 6.62 indicates that LVTX has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.62, LVTX is doing good in the industry, outperforming 66.21% of the companies in the same industry.
LVTX has a Quick Ratio of 6.62. This indicates that LVTX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.62, LVTX is doing good in the industry, outperforming 66.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.62 |
3. Growth
3.1 Past
LVTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.21%.
LVTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -65.11%.
The Revenue has been growing by 24.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-27.21%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q57.89%
Revenue 1Y (TTM)-65.11%
Revenue growth 3Y24.59%
Revenue growth 5YN/A
Revenue growth Q2Q-86.63%
3.2 Future
Based on estimates for the next years, LVTX will show a small growth in Earnings Per Share. The EPS will grow by 5.11% on average per year.
Based on estimates for the next years, LVTX will show a very strong growth in Revenue. The Revenue will grow by 25.48% on average per year.
EPS Next Y2.92%
EPS Next 2Y-14.89%
EPS Next 3Y-3.03%
EPS Next 5Y5.11%
Revenue Next Year-44.7%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y25.48%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
LVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as LVTX's earnings are expected to decrease with -3.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.89%
EPS Next 3Y-3.03%
5. Dividend
5.1 Amount
LVTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LAVA THERAPEUTICS NV
NASDAQ:LVTX (5/1/2024, 7:08:30 PM)
2.97
+0.08 (+2.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap78.08M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.27% | ||
| ROE | -82.02% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.51% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.62 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-27.21%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y2.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-65.11%
Revenue growth 3Y24.59%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y